|
1
|
Liebner DA and Shah MH: Thyroid cancer:
Pathogenesis and targeted therapy. Ther Adv Endocrinol Metab.
2:173–195. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sondermann A, Andreghetto FM, Moulatlet
AC, da Silva Victor E, de Castro MG, Nunes FD, Brandão LG and
Severino P: MiR-9 and miR-21 as prognostic biomarkers for
recurrence in papillary thyroid cancer. Clin Exp Metastasis.
32:521–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gonzalez-Gonzalez R, Bologna-Molina R,
Carreon-Burciaga RG, Gómezpalacio-Gastelum M, Molina-Frechero N and
Salazar-Rodríguez S: Papillary thyroid carcinoma: Differential
diagnosis and prognostic values of its different variants: Review
of the literature. ISRN Oncol. 2011:9159252011.PubMed/NCBI
|
|
4
|
Shi X, Liu R, Basolo F, Giannini R, Shen
X, Teng D, Guan H, Shan Z, Teng W, Musholt TJ, et al: Differential
clinicopathological risk and prognosis of major papillary thyroid
cancer variants. J Clin Endocrinol Metab. 101:264–274. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Voutilainen PE, Multanen MM, Leppäniemi
AK, Haglund CH, Haapiainen RK and Franssila KO: Prognosis after
lymph node recurrence in papillary thyroid carcinoma depends on
age. Thyroid. 11:953–957. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
He H, Jazdzewski K, Li W, Liyanarachchi S,
Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, et al:
The role of microRNA genes in papillary thyroid carcinoma. Proc
Natl Acad Sci USA. 102:pp. 19075–19080. 2005, View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maroney PA, Yu Y and Nilsen TW: MicroRNAs,
mRNAs, and translation. Cold Spring Harb Symp Quant Biol.
71:531–535. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qian Y and Wang X, Lv Z, Guo C, Yang Y,
Zhang J and Wang X: MicroRNA-126 is downregulated in thyroid cancer
cells, and regulates proliferation, migration and invasion by
targeting CXCR4. Mol Med Rep. 14:453–459. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rao M, Zhu Y, Zhou Y, Cong X and Feng L:
MicroRNA-122 inhibits proliferation and invasion in gastric cancer
by targeting CREB1. Am J Cancer Res. 7:323–333. 2017.PubMed/NCBI
|
|
12
|
Shen Y, Ye YF, Ruan LW, Bao L, Wu MW and
Zhou Y: Inhibition of miR-660-5p expression suppresses tumor
development and metastasis in human breast cancer. Genet Mol Res.
16:2017. View Article : Google Scholar
|
|
13
|
Wu D, Niu X, Pan H, Zhou Y, Qu P and Zhou
J: MicroRNA-335 is downregulated in bladder cancer and inhibits
cell growth, migration and invasion via targeting ROCK1. Mol Med
Rep. 13:4379–4385. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kent OA and Mendell JT: A small piece in
the cancer puzzle: microRNAs as tumor suppressors and oncogenes.
Oncogene. 25:6188–6196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jones KB, Salah Z, Del Mare S, Galasso M,
Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et
al: miRNA signatures associate with pathogenesis and progression of
osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Oncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang HD, Sun DW, Mao L, Zhang J, Jiang
LH, Li J, Wu Y, Ji H, Chen W, Wang J, et al: MiR-139-5p inhibits
the biological function of breast cancer cells by targeting Notch1
and mediates chemosensitivity to docetaxel. Biochem Biophys Res
Commun. 465:702–713. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang H, Yan X, Ji LY, Ji XT, Wang P, Guo
SW and Li SZ: miR-139 functions as an antioncomir to repress glioma
progression through targeting IGF-1 R, AMY-1, and PGC-1β. Technol
Cancer Res Treat. 16:497–511. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Duz MB, Karatas OF, Guzel E, Turgut NF,
Yilmaz M, Creighton CJ and Ozen M: Identification of miR-139-5p as
a saliva biomarker for tongue squamous cell carcinoma: A pilot
study. Cell Oncol (Dordr). 39:187–193. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ren Y, Zhu H, Chi C, Yang F and Xu X:
MiRNA-139 regulates oral cancer Tca8113 cells apoptosis through Akt
signaling pathway. Int J Clin Exp Pathol. 8:4588–4594.
2015.PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sponziello M, Rosignolo F, Celano M,
Maggisano V, Pecce V, De Rose RF, Lombardo GE, Durante C, Filetti
S, Damante G, et al: Fibronectin-1 expression is increased in
aggressive thyroid cancer and favors the migration and invasion of
cancer cells. Mol Cell Endocrinol. 431:123–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han Aragon P, Weng CH, Khawaja HT,
Nagarajan N, Schneider EB, Umbricht CB, Witwer KW and Zeiger MA:
MicroRNA expression and association with clinicopathologic features
in papillary thyroid cancer: A systematic review. Thyroid.
25:1322–1329. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hua K, Jin J, Zhang H, Zhao B, Wu C, Xu H
and Fang L: MicroRNA-7 inhibits proliferation, migration and
invasion of thyroid papillary cancer cells via targeting CKS2. Int
J Oncol. 49:1531–1540. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin
P, Lu Y, Li Q and Liu J: MiR-139 inhibits invasion and metastasis
of colorectal cancer by targeting the type I insulin-like growth
factor receptor. Biochem Pharmacol. 84:320–330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo H, Hu X, Ge S, Qian G and Zhang J:
Regulation of RAP1B by miR-139 suppresses human colorectal
carcinoma cell proliferation. Int J Biochem Cell Biol.
44:1465–1472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu R, Yang M, Meng Y, Liao J, Sheng J, Pu
Y, Yin L and Kim SJ: Tumor-suppressive function of miR-139-5p in
esophageal squamous cell carcinoma. PLoS One. 8:e770682013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wong CC, Wong CM, Tung EK, Au SL, Lee JM,
Poon RT, Man K and Ng IO: The microRNA miR-139 suppresses
metastasis and progression of hepatocellular carcinoma by
down-regulating Rho-kinase 2. Gastroenterology. 140:322–331. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu W, Hang M, Yuan CY, Wu FL, Chen SB and
Xue K: MicroRNA-139-5p inhibits cell proliferation and invasion by
targeting insulin-like growth factor 1 receptor in human non-small
cell lung cancer. Int J Clin Exp Pathol. 8:3864–3870.
2015.PubMed/NCBI
|
|
31
|
Song M, Yin Y, Zhang J, Zhang B, Bian Z,
Quan C, Zhou L, Hu Y, Wang Q, Ni S, et al: MiR-139-5p inhibits
migration and invasion of colorectal cancer by downregulating AMFR
and NOTCH1. Protein Cell. 5:851–861. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gu W, Li X and Wang J: miR-139 regulates
the proliferation and invasion of hepatocellular carcinoma through
the WNT/TCF-4 pathway. Oncol Rep. 31:397–404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Waalkes S, Atschekzei F, Kramer MW,
Hennenlotter J, Vetter G, Becker JU, Stenzl A, Merseburger AS,
Schrader AJ, Kuczyk MA and Serth J: Fibronectin 1 mRNA expression
correlates with advanced disease in renal cancer. BMC Cancer.
10:5032010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ruiz-Garcia E, Scott V, Machavoine C,
Bidart JM, Lacroix L, Delaloge S and Andre F: Gene expression
profiling identifies Fibronectin 1 and CXCL9 as candidate
biomarkers for breast cancer screening. Br J Cancer. 102:462–468.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jerhammar F, Ceder R, Garvin S, Grénman R,
Grafström RC and Roberg K: Fibronectin 1 is a potential biomarker
for radioresistance in head and neck squamous cell carcinoma.
Cancer Biol Ther. 10:1244–1251. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Helleman J, Jansen MP, Span PN, van
Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC,
van der Burg ME, Stoter G, et al: Molecular profiling of platinum
resistant ovarian cancer. Int J Cancer. 118:1963–1971. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nadamuni M, Piras R, Mazbar S, Higgins JP
and Kambham N: Fibronectin glomerulopathy: An unusual cause of
adult-onset nephrotic syndrome. Am J Kidney Dis. 60:839–842. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Baydar Ertoy D, Kutlugun AA, Bresin E and
Piras R: A case of familial glomerulopathy with fibronectin
deposits caused by the Y973C mutation in fibronectin. Am J Kidney
Dis. 61:514–518. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Park J and Schwarzbauer JE: Mammary
epithelial cell interactions with fibronectin stimulate
epithelial-mesenchymal transition. Oncogene. 33:1649–1657. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gao W, Liu Y, Qin R, Liu D and Feng Q:
Silence of fibronectin 1 increases cisplatin sensitivity of
non-small cell lung cancer cell line. Biochem Biophys Res Commun.
476:35–41. 2016. View Article : Google Scholar : PubMed/NCBI
|
